

Nintedanib

in Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Criteria for Use

June 2026

VA Pharmacy Benefits Management Services and National Formulary Committee

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

Inclusion Criteria

ALL the following must be selected to meet criteria.

- ☐ Prescribed and monitored by or in consultation with a VA/VA Community Care pulmonologist or rheumatologist experienced in the management of systemic sclerosis-associated interstitial lung disease (SSc-ILD)
- ☐ SSc-ILD diagnosed by a pulmonologist or rheumatologist

Original: June 2020. **Revised:** September 2020, June 2026.

Contact: Francine Goodman, PharmD, BCPS, National Program Manager, VA Pharmacy Benefits Management Services – Formulary Management (12PBM)
